Recommended

New webinar with Fujifilm: Monocyte activation test (MAT): Insight into examining regulations and markets prospects
New webinar: The path to optimisation in pharmaceutical microbiology
Join our webinar: An alternative medium to support sterility testing using the Growth Direct® Rapid Sterility System
Discover more in our new application note: validating recombinant cascade reagents in 3 simple steps

List view / Grid view

Francis Cuss

 

Bristol Myers Squibb logo
Bristol Myers Squibb logo
news

Bristol-Myers Squibb receives complete Response Letter from U.S. Food and Drug Administration for daclatasvir, an investigational treatment for Hepatitis C

Bristol-Myers Squibb Company announced that the U.S. Food and Drug…

27 November 2014 | By Bristol-Myers Squibb

Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration has issued a Complete Response Letter regarding the New Drug Application for daclatasvir, an NS5A complex inhibitor, in combination with other agents for the treatment of hepatitis C...

Bristol Myers Squibb logo
Bristol Myers Squibb logo
news

Bristol-Myers Squibb continues to lead the advancement of immuno-oncology with broad set of new data at 2014 American Society of Clinical Oncology Annual Meeting

Bristol-Myers Squibb Company announced that new data from studies investigating…

6 May 2014 | By Bristol-Myers Squibb Company

Bristol-Myers Squibb Company announced that new data from studies investigating its immunotherapies in adjuvant and advanced melanoma, non-small cell lung cancer and metastatic renal cell carcinoma will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology...